Sanofi Consumer Healthcare India Limited has informed the Exchange regarding a press release dated April 30, 2025, titled "Sanofi and CD&R close Opella transaction, create global consumer healthcare leader".
SANOFICONR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi Consumer Healthcare India has informed the stock exchanges about a press release from its Paris-based promoter, Sanofi, dated April 30, 2025, announcing the successful closing of the sale of a 50% controlling stake in Opella (its global consumer healthcare business) to private equity firm CD&R. Post-transaction, Sanofi retains a 48.2% stake in Opella, while French state investment bank Bpifrance will hold 1.8%. Sanofi received total net cash proceeds of around €10 billion from the deal. Opella, now an independent entity, is the third-largest player worldwide in the OTC and vitamins/minerals/supplements market, with brands like Allegra, Doliprane, and Dulcolax, operating in 100 countries with over 11,000 employees. Sanofi Paris has now repositioned itself as a pure-play biopharma company focused on innovative medicines and vaccines.
For Indian shareholders, the Indian listed entity continues to operate in consumer healthcare under the new global ownership structure of Opella (CD&R-led). While the immediate impact on day-to-day Indian operations may be limited, the change in controlling ownership at the global parent could eventually influence strategic decisions, capital allocation, and growth direction for the Indian business. Investors should watch for any subsequent changes in promoter shareholding or strategic direction in India.